A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Inclusion Criteria: * Male \>=18 years old. * Able to provide written informed consent and comply with the study procedures. * Participants with advanced and/or metastatic histologically or cytologically confirmed adenocarcinoma of the prostate without small cell histology. * Serum testosterone levels less than or equal to (\<=) 0.5 nanograms per millilitre (ng/mL) (\<=1.73 nanomoles per litre \[nmol/L\]) at screening if on anti-hormonal therapy. * Progression after the receipt of one or more approved second-generation androgen-receptor-pathway inhibitors with or without a prior course of tax…